MeiraGTx Holdings plc (MGTX)

4.8800 -0.0300 (-0.61%) At close: 04:00PM EDT

MeiraGTx Holdings plc

450 East 29th Street
14th Floor
New York, NY 10016
United States
646 860 7985
https://meiragtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 419

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Alexandria Forbes Ph.D.	CEO, President & Director	2.89M	N/A	1965
Mr. Richard Brian Giroux B.A.	COO & CFO	2.14M	N/A	1973
Dr. Stuart Naylor Ph.D.	Chief Development Officer	1.06M	N/A	1963
Mr. Robert J. Wollin J.D.	General Counsel & Secretary	N/A	N/A	1976
Dr. Michel Michaelides M.D.	Head of Clinical Ophthalmology	N/A	N/A	N/A
Ms. Christine Elise Sheehy	Senior Vice President of Global Integration	N/A	N/A	1968
Mr. Tim Randall	Senior Vice President of Risk & Internal Controls	N/A	N/A	N/A
Dr. Alastair Leighton Ph.D.	Senior Vice President of Manufacturing & Supply Chain	N/A	N/A	N/A
Dr. Robert K. Zeldin M.D.	Chief Medical Officer	1.1M	N/A	1963

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Corporate Governance

MeiraGTx Holdings plc’s ISS Governance QualityScore as of April 29, 2024 is 6. The pillar scores are Audit: 3; Board: 3; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.